A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

Limited Stage Small Cell Lung Cancer Clinical Trial

Official title:

An Open, Single Arm, Single Center Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Combined With Anlotinib as Maintenance Therapy in Patients With Limited Stage Small Cell Lung Cancer Without Progression After First-line Radiotherapy and Chemotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05942508
• Other study ID #: TQB2450-ALTN-Ib-02
• Status: Recruiting
• Phase: Phase 1
• Start date: May 30, 2023
• Est. completion date: February 2026

Study information

• Verified date: July 2023
• Source: Shandong Cancer Hospital and Institute
• Contact: Jin ming Yu, postdoctor
• Phone: 13806406293
• Email: sdyujinming[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who do not progress after first-line chemoradiotherapy. Based on the incidence and severity of benign and serious adverse events, as well as abnormal laboratory

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: February 2026
• Est. primary completion date: February 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• The subject voluntarily joins the study, signs the informed consent form, and has good compliance;

• Age: 18~75 years old (when signing the informed consent form); ECOG PS score: 0-1 points; Expected survival beyond 6 months; body weight> 40 kg;

• Patients with pathologically confirmed limited-stage small cell lung cancer (according to the Veterans Administration Lung Study Group (VALG stage);

• Through the neck, chest, abdomen, pelvic enhanced CT and brain plain scan + enhanced MRI examination with diagnostic quality, there is no evidence of metastatic disease (PET-CT examination is recommended before starting radiotherapy and chemotherapy, if not performed before radiotherapy and chemotherapy PET-CT examination, bone scan examination should be performed; PET-CT examination must be performed during the screening period after chemoradiotherapy to exclude metastasis);

• It is expected that no tumor resection will be required during the study (patients who are not suitable for surgery or those who are unwilling to undergo surgery are acceptable);

• Radiotherapy technology adopts three-dimensional conformal radiotherapy, conformal intensity-modulated radiotherapy, tomographic radiation therapy and other precision radiotherapy technologies;

• Patients must achieve CR, PR or SD after receiving radical platinum-based CRT and cannot develop disease progression;

• Patients with at least one measurable lesion confirmed according to RECIST 1.1 criteria prior to chemoradiotherapy;

Exclusion Criteria:

• Complex small cell lung cancer confirmed by histopathology or cytopathology;

• Subjects with known central nervous system metastasis and/or cancerous meningitis;

• Malignant pleural effusion and pericardial effusion;

• Imaging shows that the tumor has invaded important blood vessels, or the researcher has determined that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;

• Within 2 weeks before the start of the study treatment, he has received the treatment of traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the NMPA approved drug manual;

• Patients who have received immunomodulatory drugs within 30 days before starting treatment;

• Previously received anti PD-1, anti PD-L1, or anti PD-L2 drugs or medication targeting another stimulating or co inhibitory T cell receptor;

• Previous use of antivascular survival drugs( bevacizumab, arotinib, apatinib ,ect);

Related Conditions & MeSH terms

• Limited Stage Small Cell Lung Cancer
• Lung Neoplasms
• Small Cell Lung Carcinoma

Intervention

Drug:
• TQB2450 Injection + Anlotinib Hydrochloride Capsules
Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody

Locations

Country	Name	City	State
China	Cancer Hospital Affiliated to Shandong First Medical University	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Jinming Yu

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse event	Incidence and severity of adverse events	Start from the first dose until the last dose to within 84 days after the last dose or start new target indication treatment (whichever occurs first)
Primary	serious adverse event	Incidence and Severity of Serious Adverse Events	Start from the first dose until the last dose to within 84 days after the last dose or start new target indication treatment (whichever occurs first)
Secondary	Overall response rate (ORR)	ORR:According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.the proportion of subjects whose tumors are evaluated as complete response(CR) and partial response(PR) by subcenter imaging evaluation. It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment.	Up to approximately 36 months
Secondary	disease control rate	The percentage of patients who have achieved remission or stable changes in their condition after treatment compared to the evaluable cases	Up to approximately 36 months
Secondary	duration of remission	The time from the first assessment of the tumor as CR or PR to the first assessment as PD (Progressive Disease) or death from any cause	Up to approximately 36 months